Pneumothorax treatment devices market seen reaching $6.43 billion by 2030

The global pneumothorax treatment devices market is projected to grow from $3.98 billion in 2025 to $6.43 billion by 2030, driven by rising respiratory disease cases, emergency care demand and advances in chest drainage tools. North America led the market in 2025, while Asia-Pacific is positioned for faster growth as healthcare infrastructure expands.

Why it matters: - Pneumothorax treatment devices are used to treat collapsed lungs by removing trapped air and helping the lung re-expand. - Demand is rising as respiratory disease rates increase and emergency care systems face more cases requiring rapid lung decompression. - The market outlook points to sustained double-digit growth through 2030, signaling more adoption of portable and minimally invasive treatment tools.

What happened: - The Business Research Company released a report on the pneumothorax treatment devices market on August 24, 2026. - The report estimates the market will grow from $3.98 billion in 2025 to $4.39 billion in 2026. - The report forecasts the market will reach $6.43 billion by 2030. - North America held the largest market share in 2025.

The details: - The report ties historical growth to more traumatic chest injuries, more road accidents, stronger hospital emergency care, wider use of chest tube procedures and more critical care units. - Forecast growth is linked to portable emergency devices, better thoracic vent systems, higher ICU admissions, faster lung re-expansion needs and broader emergency medical service access. - The report highlights several trends: rapid emergency lung decompression, portable pneumothorax management tools, minimally invasive chest drainage techniques, stronger air leak control and simpler bedside treatment kits. - Pneumothorax treatment devices include needle decompression tools and chest tube insertion systems used in emergency and critical care settings. - The report says rising respiratory disease prevalence is a major growth driver. - The report points to air pollution, smoking, viral infections and allergen exposure as factors that worsen respiratory disease burden. - Australian Bureau of Statistics data cited in the report showed influenza-related deaths rose from 611 in 2023 to 806 in 2024 and to 1,057 by August 2025. - The same data set showed RSV-related deaths increased from 380 in 2023 to 468 in 2024, with 399 reported by August 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report says Asia-Pacific and other emerging regions have strong growth potential because of expanding healthcare infrastructure and rising respiratory disease incidence. - New report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - The report offers a free sample and the full report.

Between the lines: - The report suggests the market is being pushed by both chronic respiratory disease pressure and acute trauma-related demand. - Portable devices and minimally invasive drainage systems appear to be the clearest product themes shaping future competition. - North America’s current lead likely reflects stronger emergency-care capacity, while faster percentage growth may come from markets still building that infrastructure.

What's next: - The market is expected to keep growing at about a 10.0% CAGR through 2030. - Product development is likely to focus on bedside kits, portable decompression tools and better air leak control. - Adoption should continue to rise as emergency services and ICU access expand in more regions.

The bottom line: - Pneumothorax treatment devices are moving from niche emergency tools to a broader, fast-growing global category as respiratory illness and trauma care needs increase.